SERA PROGNOSTICS INC-A (SERA) Stock Price, Quote, News and Overview
NASDAQ:SERA - Nasdaq - US81749D1072 - Common Stock - Currency: USD
SERA Quote, Performance and Key Statistics
SERA PROGNOSTICS INC-A
NASDAQ:SERA (2/10/2025, 8:22:39 PM)
Premarket: 3.74 -0.71 (-15.96%)4.45
-0.09 (-1.98%)
The current stock price of SERA is 4.45 USD. In the past month the price decreased by -35.79%. In the past year, price decreased by -54.17%.
SERA Latest News and Analysis
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the past week and a look at the reasons why and what's next.
SERA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.81 | 336.36B | ||
| AMGN | AMGEN INC | 14.87 | 158.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1620.59 | 121.03B | ||
| GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.73 | 20.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Related stock screener links
About SERA
Company Profile
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 57 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
Company Info
SERA PROGNOSTICS INC-A
2749 E. Parleys Way, Suite 200
Salt Lake City UTAH US
CEO: Gregory C. Critchfield
Employees: 56
Company Website: https://www.seraprognostics.com/
Investor Relations: https://seraprognostics.com/investors/
Phone: 18015050278
SERA FAQ
What is the stock price of SERA?
The current stock price of SERA is 4.45 USD.
What is the symbol for SERA PROGNOSTICS INC-A stock?
The exchange symbol of SERA PROGNOSTICS INC-A is SERA and it is listed on the Nasdaq exchange.
On which exchange is SERA stock listed?
SERA stock is listed on the Nasdaq exchange.
Is SERA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SERA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SERA.
Does SERA stock pay dividends?
SERA does not pay a dividend.
What is the Price/Earnings (PE) ratio of SERA?
SERA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the Short Interest ratio of SERA stock?
The outstanding short interest for SERA is 2.95% of its float.
SERA Technical Analysis
SERA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SERA. SERA has a bad profitability rating. Also its financial health evaluation is rather negative.
SERA Financial Highlights
Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS decreased by 18.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.81% | ||
| ROE | -59% | ||
| Debt/Equity | 0 |
SERA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to SERA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 14.27% and a revenue growth -69.01% for SERA